Oxidized LDL ELISA
Kit format: 1 x 96 wells
Measurement range: 1.00 - 25.0 mU/L (6.56 - 164 U/L when multiplied with dilution factor)
CE/IVD labeled on selected markets
Controls included in the kit
The unique specificity of antibody 4E6 enables measurement of all highly oxidized LDL, independent of other modifications of LDL
The Mercodia Oxidized LDL ELISA kit is intended to be used for in vitro quantification of oxidized low-density lipoproteins (oxidized LDL) in human serum or plasma.
Mercodia Oxidized LDL ELISA is a unique sandwich ELISA based on the proprietary mouse monoclonal antibody 4E6, which is directed against a conformational epitope in oxidized ApoB-100. Elevated plasma levels of oxidized LDL are associated with higher cardiovascular risk and higher incidence of metabolic diseases, i.e. metabolic syndrome, obesity and type 2 diabetes. Also sub-clinical atherosclerosis, kidney and liver diseases are associated with increased levels of oxidized LDL.
1.00-25.0 mU/L (6.56-164 U/L when multiplied with dilution factor)
≤ 0.5 mU/L
2 h +1 h + 15 min
The following cross-reactions have been tested:
The proprietary mouse monoclonal antibody 4E6 is developed by professors Holvoet and Collen at the University of Leuven in Belgium. It is directed against a conformational epitope in the ApoB100 moiety of LDL that is generated as a consequence of substitution of at least 60 lysine residues of Apo B100 with aldehydes (Holvoet 2006). This number of substituted lysines corresponds to the minimal number required for scavenger-mediated uptake of oxidized LDL. Substituting aldehydes can be produced by peroxidation of lipids of LDL, resulting in the generation of oxidized LDL. However, lipid peroxidation is not required. Indeed, aldehydes that are released by endothelial cells under oxidative stress or by activated platelets may also induce the oxidative modification of Apo B100 in the absence of lipid peroxidation of LDL. The unique affinity of the antibody 4E6 used in the Mercodia Oxidized LDL ELISA makes it possible to measure both MDA and aldehyde modified oxidized LDL, which sets this assay apart from assays based on other antibodies.
For other languages and older versions:Technical Library
For other technical notes see our Technical Library
Holvoet, P. (2006) Obesity, the metabolic syndrome, and oxidized LDL. Am J Clin Nutr 83, 1438; author reply 1438-9. Read more >
Jin, R. et al. (2014) Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients 6, 3187–3201. Read more >
Dias, J. A. et al. (2016) Low-grade inflammation, oxidative stress and risk of invasive post-menopausal breast cancer - A nested case-control study from the Malmö diet and cancer cohort. PLoS One 11, e0158959. Read more >
Soran, H. et al. (2018) A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. J. Clin. Lipidol. 12, 44–55. Read more >
Khatana, C., Saini, N. K., Chakrabarti, S., Saini, V., Sharma, A., Saini, R. V., & Saini, A. K. (2020). Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis. Oxidative medicine and cellular longevity, 2020, 5245308. 12, 44–55. Read more >
Oxidized LDL ELISA